2017, Volume 19, Issue 2
Strategic Study of CAE >> 2017, Volume 19, Issue 2 doi: 10.15302/J-SSCAE-2017.02.005
Strategic Research on the Molecular Diagnostics Industry in China
Medical Systems Biology Research Center, School of Medicine, Tsinghua University, Beijing 100084, China
Next Previous
Abstract
Molecular diagnostics is an important part of personalized medicine and has become the main driving force of the in vitro diagnostics industry. In recent years, China's molecular diagnostics industry has been growing rapidly, despite its small size. Based on literature research, expert interviews, and field investigation, we performed an intensive market analysis of the current situation of the domestic molecular diagnostics industry. The aim of this study is to explore the characteristics of the domestic molecular diagnostics industry; identify opportunities and challenges in innovation, industrial transformation, and related policies and regulations; and propose approaches to overcome existing constraints under the current administrative system. This analysis is of great significance for promoting the development of China’s molecular diagnostics industry.
Keywords
molecular diagnostics ; in vitro diagnostics ; market analysis ; policies and regulations ; biochip
Figures
Fig. 1
Fig. 2
References
[ 1 ] Lv J X. The application prospect of molecular diagnostics in lab-oratory medicine [J]. Chinese Journal of Laboratory Medicine, 2005, 28(2): 137–139. Chinese.
[ 2 ] The worldwide in vitro diagnostic market will reach $74.7 billion by 2020 [J]. China Pharmaceutical Technology Economics & Management, 2014(3): 16. Chinese.
[ 3 ] Yi Y. The expansion of molecular diagnostics market has a prom-ising prospect [N]. Medical Economic News, 2011-06-17(A02). Chinese.
[ 4 ] Wang Y. Chinese and foreign brands compete for the 20 billion in vitro diagnostics market in China [N]. China business news, 2015-06-09. Chinese.
[ 5 ] Wang L. Project report of molecular diagnostics industry: Ex-ploring the mystery of life, molecular diagnostic will outbreak in the future [R]. Guangzhou: Card Hang Seng Securities, 2016. Chinese.
[ 6 ] Huggett J F, Cowen S, Foy C A. Considerations for digital PCR as an accurate molecular diagnostic tool [J]. Clinical Chemistry, 2015, 61(1): 79–88.
[ 7 ] Harris T D, Buzby P R, Babcock H, et al. Single-molecule DNA sequencing of a viral genome [J]. Science, 2008, 320(5872): 106–109. link1
[ 8 ] Yang K, Zhang X Q, Song Y, et al. Molecular imaging techniques and applications [J]. Journal of Henan Education Institute, 2010, 19(4): 17–20. Chinese.
[ 9 ] Su X, Cheng K, Jeon J, et al. Comparison of two site-specifcally 18F-labeled antibodies for PET imaging of EGFR positive tumors [J]. Molecular Pharmaceutics, 2014, 11(11): 3947–3956. link1
[10] Fu W L, Luo Y. Application of molecular diagnostics in noso-comial infection [J]. Chinese Journal of Nosocomiology, 2009, 19(14):1771–1775. Chinese. link1
[11] Wang Y. Biochip market—2016 [R]. Shanghai: MEMS Consult-ing, 2016. Chinese.
[12] Sohu.com. The biochip industry market is expected to reach $900 million in 2020 [EB/OL]. (2015-06-26) [2016-11-15]. http://mt.so-hu.com/20150626/n415693087.shtml. Chinese.
[13] Gene Valley. Ranking of gene detection companies [EB/OL]. (2016-11-24) [2016-12-05]. http://www.genegood.com/a/view/667.html. Chinese.
[14] Tang X L. Domestic and foreign enterprises competing admission into molecular diagnostics industry in China [N]. Medicine Eco-nomic News, 2012-11-26 (A03). Chinese.
[15] Zhang X. The complicated situation of IVD industry in China [N]. China Pharmaceutical News, 2007-11-14. Chinese.
[16] Li Y H, Zhang S Q. Retrospect and prospect of in vitro diagnos-tic reagent industry [J]. Laboratory Medicine and Clinic, 2017, 14(2):299–301. Chinese. link1
[17] Changjiang Securities. IVD industry depth report: A rising indus-try [EB/OL]. (2015-07-29) [2016-11-15]. http://www.bioon.com/trends/news/613619_2.shtml. Chinese.
京公网安备 11010502051620号
